Immunome (IMNM) Current Assets (2019 - 2026)

Immunome has reported Current Assets for 8 years, with the latest figure at $594.3 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 83.92% year-over-year to $594.3 million; the trailing twelve-month figure through Mar 2026 stood at $594.3 million (up 83.92% YoY), and the FY2025 full-year result was $660.8 million, up 198.54% from the prior year.
• Current Assets for Q1 2026 stood at $594.3 million, down from $660.8 million in the prior quarter.
• The five-year high for Current Assets was $660.8 million in Q4 2025, with the low at $22.6 million in Q4 2022.
• Historically, Current Assets has averaged $215.1 million across 5 years, with a median of $221.3 million in 2024.
• Annual changes were most pronounced in 2022 — Current Assets sank 60.01% — and 2024, when it surged 619.23%.
• Immunome's Current Assets stood at $22.6 million in 2022, then soared by 538.89% to $144.7 million in 2023, then soared by 52.96% to $221.3 million in 2024, then jumped by 198.54% to $660.8 million in 2025, then decreased by 10.06% to $594.3 million in 2026.
• The last three Current Assets figures came in at $594.3 million (Q1 2026), $660.8 million (Q4 2025), and $279.9 million (Q3 2025), per Business Quant data.